Showing results (31-40 of 46) with videos related to

Sort By:
Pageof 5
European Journal of Cancer (Oxford, England : 1990)|July 17, 2024
Long term survival in adult osteosarcoma patients treated with a two-drug regimen: Final results of the OSAD93 phase II study of the FSG-GETOJean-Yves Blay, Nicolas Penel, Maud Toulmonde, et al.
BMC Cancer|November 7, 2015
Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes)Mathilde Penel-Page, Isabelle Ray-Coquard, Julie Larcade, et al.
The Lancet. Oncology|February 21, 2020
Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trialAntoine Italiano, Olivier Mir, Simone Mathoulin-Pelissier, et al.
The Lancet. Oncology|August 20, 2021
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 studyNathalie Gaspar, Rajkumar Venkatramani, Stefanie Hecker-Nolting, et al.
Journal of Clinical Pharmacology|May 24, 2018
A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 TrialGabrielle Lui, Jean-Marc Treluyer, Brice Fresneau, et al.
Cancer Research|January 26, 2022
Immune Infiltrate and Tumor Microenvironment Transcriptional Programs Stratify Pediatric Osteosarcoma into Prognostic Groups at DiagnosisAntonin Marchais, Maria Eugenia Marques da Costa, Bastien Job, et al.
Pediatric Blood & Cancer|October 10, 2024
Li-Fraumeni-associated osteosarcomas: The French experienceEmilie Saucier, Gaëlle Bougeard, Anne Gomez-Mascard, et al.
The Lancet. Oncology|June 22, 2016
Zoledronate in combination with chemotherapy and surgery to treat osteosarcoma (OS2006): a randomised, multicentre, open-label, phase 3 trialSophie Piperno-Neumann, Marie-Cécile Le Deley, Françoise Rédini, et al.
European Journal of Cancer (Oxford, England : 1990)|December 1, 2017
Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 studyNathalie Gaspar, Bob-Valéry Occean, Hélène Pacquement, et al.
International Journal of Cancer|October 17, 2022
Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in FranceVictoria Corvest, Perrine Marec-Bérard, Cyril Lervat, et al.
Pageof 5